Cargando…

Immunoadsorption Column Reuse

INTRODUCTION: Selective immunoadsorption (IA) is a technique to remove preformed Anti-ABO antibodies in ABO-incompatible renal transplants (ABOiRT). Since the cost of a single IA column is high and single use rarely achieves the target anti-ABO titers, its use is not widely spread. We studied the sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Tiwari, Vaibhav, Gupta, Anurag, Divyaveer, Smita, Bhargava, Vinant, Malik, Manish, Gupta, Ashwani, Bhalla, Anil K., Rana, D S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101676/
https://www.ncbi.nlm.nih.gov/pubmed/33994685
http://dx.doi.org/10.4103/ijn.IJN_373_19
_version_ 1783688992818987008
author Tiwari, Vaibhav
Gupta, Anurag
Divyaveer, Smita
Bhargava, Vinant
Malik, Manish
Gupta, Ashwani
Bhalla, Anil K.
Rana, D S
author_facet Tiwari, Vaibhav
Gupta, Anurag
Divyaveer, Smita
Bhargava, Vinant
Malik, Manish
Gupta, Ashwani
Bhalla, Anil K.
Rana, D S
author_sort Tiwari, Vaibhav
collection PubMed
description INTRODUCTION: Selective immunoadsorption (IA) is a technique to remove preformed Anti-ABO antibodies in ABO-incompatible renal transplants (ABOiRT). Since the cost of a single IA column is high and single use rarely achieves the target anti-ABO titers, its use is not widely spread. We studied the safety and efficacy of the reuse of IA columns in ABOiRT. METHODS: Single-center, retrospective analysis of all patients who underwent ABOiRT with IA column reuse from January 2016 to July 2018. The column was reused after sterilization with ethylene oxide and flushed with normal saline before use. Target titers (IgG) were 1:4 preoperatively. Baseline IgG titers, plasma volume processed in each session, postoperative titer rebound were recorded. The primary outcome was IgG titer reduction after each use and adverse reaction during the IA column reuse. Patients were followed up until 1 year. RESULTS: 16 patients underwent ABOiRT using IA columns. Baseline IgG titer ranged from 1:32 to 1:512. Reuse of IA column was done 23 times and underwent 2(nd) reuse for 9 times. The average plasma volume treated was 22 L. Efficacy of the IA column in log titer reduction of anti-ABO titer was 4 logs after the first use, 3 logs after 1(st) reuse, and 1.5 logs after 2(nd) reuse. 12 (75%) patients successfully reached the target IgG titer of ≤1:4 solely with column reuse. One patient received a single session of plasma exchange before transplantation. Postoperatively, one patient received one session of plasma exchange due to a rebound in anti-ABO antibodies. No serious side effects were noted during the reuse. CONCLUSION: IA column reuse up to two times showed efficacy in the successful reduction of antibody titers. Column reuse was not associated with any significant side effects.
format Online
Article
Text
id pubmed-8101676
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-81016762021-05-13 Immunoadsorption Column Reuse Tiwari, Vaibhav Gupta, Anurag Divyaveer, Smita Bhargava, Vinant Malik, Manish Gupta, Ashwani Bhalla, Anil K. Rana, D S Indian J Nephrol Original Article INTRODUCTION: Selective immunoadsorption (IA) is a technique to remove preformed Anti-ABO antibodies in ABO-incompatible renal transplants (ABOiRT). Since the cost of a single IA column is high and single use rarely achieves the target anti-ABO titers, its use is not widely spread. We studied the safety and efficacy of the reuse of IA columns in ABOiRT. METHODS: Single-center, retrospective analysis of all patients who underwent ABOiRT with IA column reuse from January 2016 to July 2018. The column was reused after sterilization with ethylene oxide and flushed with normal saline before use. Target titers (IgG) were 1:4 preoperatively. Baseline IgG titers, plasma volume processed in each session, postoperative titer rebound were recorded. The primary outcome was IgG titer reduction after each use and adverse reaction during the IA column reuse. Patients were followed up until 1 year. RESULTS: 16 patients underwent ABOiRT using IA columns. Baseline IgG titer ranged from 1:32 to 1:512. Reuse of IA column was done 23 times and underwent 2(nd) reuse for 9 times. The average plasma volume treated was 22 L. Efficacy of the IA column in log titer reduction of anti-ABO titer was 4 logs after the first use, 3 logs after 1(st) reuse, and 1.5 logs after 2(nd) reuse. 12 (75%) patients successfully reached the target IgG titer of ≤1:4 solely with column reuse. One patient received a single session of plasma exchange before transplantation. Postoperatively, one patient received one session of plasma exchange due to a rebound in anti-ABO antibodies. No serious side effects were noted during the reuse. CONCLUSION: IA column reuse up to two times showed efficacy in the successful reduction of antibody titers. Column reuse was not associated with any significant side effects. Wolters Kluwer - Medknow 2021 2020-11-07 /pmc/articles/PMC8101676/ /pubmed/33994685 http://dx.doi.org/10.4103/ijn.IJN_373_19 Text en Copyright: © 2020 Indian Journal of Nephrology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Tiwari, Vaibhav
Gupta, Anurag
Divyaveer, Smita
Bhargava, Vinant
Malik, Manish
Gupta, Ashwani
Bhalla, Anil K.
Rana, D S
Immunoadsorption Column Reuse
title Immunoadsorption Column Reuse
title_full Immunoadsorption Column Reuse
title_fullStr Immunoadsorption Column Reuse
title_full_unstemmed Immunoadsorption Column Reuse
title_short Immunoadsorption Column Reuse
title_sort immunoadsorption column reuse
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101676/
https://www.ncbi.nlm.nih.gov/pubmed/33994685
http://dx.doi.org/10.4103/ijn.IJN_373_19
work_keys_str_mv AT tiwarivaibhav immunoadsorptioncolumnreuse
AT guptaanurag immunoadsorptioncolumnreuse
AT divyaveersmita immunoadsorptioncolumnreuse
AT bhargavavinant immunoadsorptioncolumnreuse
AT malikmanish immunoadsorptioncolumnreuse
AT guptaashwani immunoadsorptioncolumnreuse
AT bhallaanilk immunoadsorptioncolumnreuse
AT ranads immunoadsorptioncolumnreuse